Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829152 | 0.85 | SMN1; SMN2 (0.36) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL15221425 | 0.84 | SMN1; SMN2 (0.36) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL14999473 | 0.83 | SMN1; SMN2 (0.40) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL9954167 | 0.81 | CYP1A2 (0.43) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL27892076 | 0.79 | CYP1A2 (0.42) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL27755650 | 0.79 | MMP8 (0.41) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 | |
| SCHEMBL14690401 | 0.77 | KDM4E (0.42) | KDM4EHSD17B10HPGDTSHRCYP3A4 | |
| SCHEMBL7839246 | 0.73 | SMN1; SMN2 (0.46) | KDM4ETSHRSMN1; SMN2MAPTCTSS | |
| SCHEMBL9232122 | 0.73 | OPRM1 (0.58) | HSD17B10TSHRSMN1; SMN2CYP3A4MEN1 | |
| SCHEMBL8557818 | 0.73 | SIGMAR1 (0.40) | KDM4EHSD17B10HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-10125141-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-11-13 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-20190023715-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | KDM4E 796/4885HSD17B10 233/4885HPGD 636/4885 |
| US-10125141-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
| US-20170204109-A1 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | KDM4E 3774/4885HSD17B10 758/4885HPGD 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.